Zarina Mamieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zarina Mamieva has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Elena A. Poluektova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Oleg S. Shifrin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Vladimir Trofimovich Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - A. L. Kovaleva
Sechenov First Moscow State University (Sechenov University)
2 shared publications - Anatoly I. Ulyanin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Aiman Silkanovna Sarsenbaeva
South Ural State Medical University
1 shared publication
Latest Publications
- Open Access
- 7 October 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 88-97
Results of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice
Aim: to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease.Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale.Results. Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period.Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.
- 7 October 2025
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 88-97
Open AccessResults of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice
Aim: to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease.Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale.Results. Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period.Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.
- Open Access
- 4 December 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (5) , 47-58
Effects of Bifidobacterium longum longum 35624® on the Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome: Results of the Multicenter Observational Program SAGA
Aim: to evaluate the effects of the probiotic Symbiosys Alflorex (Bifidobacterium longum longum 35624®) on the symptoms and quality of life in patients with irritable bowel syndrome (IBS).Materials and methods. A multicenter, observational program (SAGA) was conducted to evaluate the effects of Symbiosys Alflorex on symptoms and quality of life in patients with IBS, which enrolled 3,116 patients and 246 physicians from 48 cities of Russia. Eligible patients were diagnosed with IBS according to the Rome IV Criteria and clinical guidelines of the Russian Association of Gastroenterology and the Association of Colorectal Surgeons of Russia. Patients received standard-of-care treatment and add-on therapy with Symbiosys Alflorex 1 capsule once daily for 28 days, followed by Symbiosys Alflorex alone for 2 months. The intensity of symptoms and severity of IBS were assessed using the 7 Symptoms in 7 Days (“7 × 7”) and the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) questionnaires, respectively. The Irritable Bowel Syndrome Quality of Life (IBS-QоL) questionnaire was used to assess the quality of life. Stool abnormalities were assessed using the Bristol Stool Scale.Results. After the course of standard-of-care treatment and add-on therapy with Symbiosys Alflorex, 25.8 % of patients achieved clinical remission. After 3 months of probiotic treatment, 76.9 % of patients achieved clinical remission. A significant decrease in the “7 × 7” score was observed, with the mean total score decreasing from 15.8 to 9.77 after the main treatment course and to 3.44 by the end of the study. Stool consistency became normal in 40.1 % of patients by the end of the first month and in 76.8 % after 3 months of follow-up. Changes in the IBS-QoL score showed a significant improvement in the quality of life.Conclusions. Add-on treatment with Symbiosys Alflorex 1 capsule once daily for 3 months helps to improve IBS symptoms and quality of life of patients. Symbiosys Alflorex has a favorable safety profile.
- 4 December 2024
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 34 (5) , 47-58
Open AccessEffects of Bifidobacterium longum longum 35624® on the Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome: Results of the Multicenter Observational Program SAGA
Aim: to evaluate the effects of the probiotic Symbiosys Alflorex (Bifidobacterium longum longum 35624®) on the symptoms and quality of life in patients with irritable bowel syndrome (IBS).Materials and methods. A multicenter, observational program (SAGA) was conducted to evaluate the effects of Symbiosys Alflorex on symptoms and quality of life in patients with IBS, which enrolled 3,116 patients and 246 physicians from 48 cities of Russia. Eligible patients were diagnosed with IBS according to the Rome IV Criteria and clinical guidelines of the Russian Association of Gastroenterology and the Association of Colorectal Surgeons of Russia. Patients received standard-of-care treatment and add-on therapy with Symbiosys Alflorex 1 capsule once daily for 28 days, followed by Symbiosys Alflorex alone for 2 months. The intensity of symptoms and severity of IBS were assessed using the 7 Symptoms in 7 Days (“7 × 7”) and the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) questionnaires, respectively. The Irritable Bowel Syndrome Quality of Life (IBS-QоL) questionnaire was used to assess the quality of life. Stool abnormalities were assessed using the Bristol Stool Scale.Results. After the course of standard-of-care treatment and add-on therapy with Symbiosys Alflorex, 25.8 % of patients achieved clinical remission. After 3 months of probiotic treatment, 76.9 % of patients achieved clinical remission. A significant decrease in the “7 × 7” score was observed, with the mean total score decreasing from 15.8 to 9.77 after the main treatment course and to 3.44 by the end of the study. Stool consistency became normal in 40.1 % of patients by the end of the first month and in 76.8 % after 3 months of follow-up. Changes in the IBS-QoL score showed a significant improvement in the quality of life.Conclusions. Add-on treatment with Symbiosys Alflorex 1 capsule once daily for 3 months helps to improve IBS symptoms and quality of life of patients. Symbiosys Alflorex has a favorable safety profile.
- Open Access
- 15 May 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (2) , 35-44
The Effectiveness of Add-on Treatment with Nutraceutical
Aim:evaluation of the effectiveness of the nutraceutical “Standard Zdorovia: Gastro” (“SZ Gastro”) in the treatment of patients with irritable bowel syndrome (IBS).Materials and methods.52 patients (62 % women) diagnosed with IBS and IBS in combination with functional dyspepsia (FD) were included in the study and divided into two groups. Both groups received basic therapy according to the guidelines. The experimental group received as add-on the nutraceutical “SZ Gastro” (containing a standardized amount of menthol, gingerol and D-limonene); patients in the control group — placebo. The duration of the study was 30 days. The severity of somatic symptoms was assessed with the 7×7 questionnaire. Emotional state was assessed with the Four Dimensional Distress, Depression, Anxiety, and Somatization Questionnaire (4DSQ).Results.Patients of the experimental and control groups did not differ from each other either in terms of demographics, basic treatment, or in the severity of symptoms at the beginning of the study.The effectiveness of the treatment in the patients, who received add-on “SZ Gastro” was significantly higher than in the patients of the control group: in the control group the percentage of improvement of somatic symptoms was 22.35 %, in the experimental group it amounted to 49.18 % (χ2= 15.9;p= 0.0001). The percentage of patients with significant decrease of emotional disturbances was also higher in the experimental group: distress (χ2= 18.7;p= 0.0000), anxiety (χ2= 6.9;p= 0.0097) and somatization (χ2= 14.99;p= 0.0001). No significant side effects were registered in any of the groups.Conclusions.Add-on of nutraceutical “SZ Gastro” to basic treatment is safe and significantly increases effectiveness of the therapy in the patients with IBS and IBS in combination with PD.
- 15 May 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 32 (2) , 35-44
Open AccessThe Effectiveness of Add-on Treatment with Nutraceutical
Aim:evaluation of the effectiveness of the nutraceutical “Standard Zdorovia: Gastro” (“SZ Gastro”) in the treatment of patients with irritable bowel syndrome (IBS).Materials and methods.52 patients (62 % women) diagnosed with IBS and IBS in combination with functional dyspepsia (FD) were included in the study and divided into two groups. Both groups received basic therapy according to the guidelines. The experimental group received as add-on the nutraceutical “SZ Gastro” (containing a standardized amount of menthol, gingerol and D-limonene); patients in the control group — placebo. The duration of the study was 30 days. The severity of somatic symptoms was assessed with the 7×7 questionnaire. Emotional state was assessed with the Four Dimensional Distress, Depression, Anxiety, and Somatization Questionnaire (4DSQ).Results.Patients of the experimental and control groups did not differ from each other either in terms of demographics, basic treatment, or in the severity of symptoms at the beginning of the study.The effectiveness of the treatment in the patients, who received add-on “SZ Gastro” was significantly higher than in the patients of the control group: in the control group the percentage of improvement of somatic symptoms was 22.35 %, in the experimental group it amounted to 49.18 % (χ2= 15.9;p= 0.0001). The percentage of patients with significant decrease of emotional disturbances was also higher in the experimental group: distress (χ2= 18.7;p= 0.0000), anxiety (χ2= 6.9;p= 0.0097) and somatization (χ2= 14.99;p= 0.0001). No significant side effects were registered in any of the groups.Conclusions.Add-on of nutraceutical “SZ Gastro” to basic treatment is safe and significantly increases effectiveness of the therapy in the patients with IBS and IBS in combination with PD.
- Open Access
- 28 March 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (12) , 1204-1219
Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?
Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?
- 28 March 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (12) , 1204-1219
Open AccessAntibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?
Antibiotics, gut microbiota, and irritable bowel syndrome: What are the relations?
- Open Access
- 2 January 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 31 (5) , 66-73
Colorectal Cancer in Patient with Functional Gastrointestinal Symptoms
Aim. A clinical observation to highlight the importance of detailed examination in patients with functional gastrointestinal symptoms.Key points. A 28-yo female patient was admitted with complains of left ileal pain, abdominal distention and up to 4-day stool delay. The complaints had long been interpreted as clinical manifestations of irritable bowel syndrome. No significant abnormalities were revealed in outpatient check-up (general and biochemical blood panels, stool test, abdominal ultrasound, oesophagogastroduodenoscopy). Colonoscopy was performed on admission, with diagnosis of rectal adenocarcinoma. The patient had a prompt surgical intervention, repeated courses of polychemotherapy and is currently followed by an oncologist and coloproctologist. No relapse signs have been reported.Conclusion. Patients with the complaints satisfying the Rome Criteria Revision IV for functional gastrointestinal diseases should have a thorough examination as per recommendations of the Russian Gastroenterological Association and Russian Association of Coloproctologists.
- 2 January 2022
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 31 (5) , 66-73
Open AccessColorectal Cancer in Patient with Functional Gastrointestinal Symptoms
Aim. A clinical observation to highlight the importance of detailed examination in patients with functional gastrointestinal symptoms.Key points. A 28-yo female patient was admitted with complains of left ileal pain, abdominal distention and up to 4-day stool delay. The complaints had long been interpreted as clinical manifestations of irritable bowel syndrome. No significant abnormalities were revealed in outpatient check-up (general and biochemical blood panels, stool test, abdominal ultrasound, oesophagogastroduodenoscopy). Colonoscopy was performed on admission, with diagnosis of rectal adenocarcinoma. The patient had a prompt surgical intervention, repeated courses of polychemotherapy and is currently followed by an oncologist and coloproctologist. No relapse signs have been reported.Conclusion. Patients with the complaints satisfying the Rome Criteria Revision IV for functional gastrointestinal diseases should have a thorough examination as per recommendations of the Russian Gastroenterological Association and Russian Association of Coloproctologists.
- Open Access
- 3 December 2019
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 29 (5) , 13-20
New Possibilities for the Treatment of Crohn’s Disease
Aim. To review data on the efficiency and safety of using Ustekinumab in patients with Crohn’s disease.Key findings. Ustekinumab is a fully human monoclonal antibody of the IgG1k class to the p40 subunit of IL-12 and IL-23. The drug interrupts the cascade of humoral and cellular reactions leading to transmural inflammation of the intestinal wall by blocking the interaction of the p40 subunit with the IL-12Rβ1 chain on the surface of T-lymphocytes and NK cells. A number of placebo-controlled studies have demonstrated the effectiveness of Ustekinumab in the induction and the maintenance of remission in those patients with Crohn’s disease who showed no response to conventional therapy (glucocorticosteroids and immunosuppressants) and therapy with TNF-α antagonists. In addition, the efficiency of Ustekinumab in maintaining a clinical response and clinical remission over two years of therapy has been shown. The drug has a favourable safety profile and a low immunogenicity.Conclusion. The reviewed studies show Ustekinumab to be an effective and safe drug for the induction and the maintenance of clinical remission in patients with Crohn’s disease.
- 3 December 2019
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 29 (5) , 13-20
Open AccessNew Possibilities for the Treatment of Crohn’s Disease
Aim. To review data on the efficiency and safety of using Ustekinumab in patients with Crohn’s disease.Key findings. Ustekinumab is a fully human monoclonal antibody of the IgG1k class to the p40 subunit of IL-12 and IL-23. The drug interrupts the cascade of humoral and cellular reactions leading to transmural inflammation of the intestinal wall by blocking the interaction of the p40 subunit with the IL-12Rβ1 chain on the surface of T-lymphocytes and NK cells. A number of placebo-controlled studies have demonstrated the effectiveness of Ustekinumab in the induction and the maintenance of remission in those patients with Crohn’s disease who showed no response to conventional therapy (glucocorticosteroids and immunosuppressants) and therapy with TNF-α antagonists. In addition, the efficiency of Ustekinumab in maintaining a clinical response and clinical remission over two years of therapy has been shown. The drug has a favourable safety profile and a low immunogenicity.Conclusion. The reviewed studies show Ustekinumab to be an effective and safe drug for the induction and the maintenance of clinical remission in patients with Crohn’s disease.